Lepu Biopharma: Puyouheng (pucotenlimab injection) obtains approval for marketing with a new indication, Breakthrough therapy designation granted by the CDE to MRG003 for the treatment of R/M NPC
HONG KONG, Sep 29, 2022 - (ACN Newswire) - LEPU BIOPHARMA (2157.HK) announced that its first innovative biological drug, anti-PD-1 antibody Puyouheng (generic name: pucotenlimab injection) has been approved for marketing by the National Medical Products Administration (NMPA) for the indication of unresectable or metastatic melanomas after the failure of previous systemic therapy. It is another approved indication for Puyouheng (pucotenlimab injection) following the approval of the indication of MSI-H/dMMR solid tumor in July this year and will bring a new immunotherapy treatment option for patients with melanoma in China. The Company is also pleased to announce that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People's Republic of China (PRC) has granted MRG003 breakthrough therapy designation for the treatment of recurrent or metastatic nasopharyngeal cancer (R/M NPC).
Bringing a new option to tumor immunotherapy for patients
This approval was mainly based on a single-arm, open-label, pivotal phase II clinical study with a primary endpoint of the objective response rate (ORR) assessed by the Independent Review Committee (IRC) according to the RECIST 1.1. A total of 119 patients were enrolled in this trial. As of July 30, 2021, the ORR assessed by the IRC was 20.2% (95% CI: 13.4-28.5, 1 case of complete response, 23 cases of partial response). The results of the study show that Puyouheng brings significant benefits to patients in the treatment of unresectable or metastatic melanomas after the failure of previous systemic therapy, and meets the preset primary endpoint with excellent safety. The results of the clinical study were first published at the 2021 American Society of Clinical Oncology (ASCO) annual meeting.
Melanoma is a malignant tumor of melanocytes. Although melanoma only accounts for less than 5% of skin cancers, it is the deadliest form which takes up more than 75% of all deaths caused by skin cancers. Surgical treatment is the main option for malignant melanomas in the early stage with a better prognosis, while the treatment of advanced melanomas is limited with a poor prognosis. As an innovative anti-PD-1 humanized monoclonal antibody drug, Puyouheng innovatively prolongs its half-life through triple mutations and can bind to PD-1 with high affinity to restore the ability of immune cells to kill cancer cells by blocking the binding of PD-1 to its ligands PD-L1 and PD-L2.
With a strong affinity to PD-1 and outstanding binding stability, Puyouheng has demonstrated excellent anti-tumor efficacy in both in vitro and clinical trials.
Actively conducting studies on the combination therapy within our pipelines under the support of a clinical layout covering multiple solid tumors
Puyouheng has been approved for marketing with indications of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors and advanced melanomas. In addition to the two approved indications, focusing on Puyouheng, LEPU BIOPHARMA is accelerating its development in the treatment of multiple solid tumors and actively investigating combined tumor immune immunotherapies, including the treatment of gastric cancer, liver cancer, lung cancer, and other cancer types with high incidence. In terms of international development, LEPU BIOPHARMA is also speeding up its efforts to expand the international market, promoting joint development, cooperation and authorization of new drugs globally. In January 2022, it obtained IND approval from the US FDA for pucotenlimab in the treatment of advanced solid tumors.
Breakthrough therapy designation granted by the CDE to MRG003 for the treatment of R/M NPC Breakthrough therapy designation is for innovative or modified new drugs that treat a condition that is seriously life-threatening or has serious quality-of-life impairment, and such condition has no effective therapies or compared with current available therapies, sufficient evidence demonstrates an obvious advantage in clinic treatment of the new drugs.
Previously, MRG003 has been granted the Orphan-drug Designation by the Food and Drug Administration of the United States (the "FDA") for the treatment of R/M NPC. MRG003 is the most advanced EGFR-targeted ADC in clinical-stage development in China and has the potential to seize market opportunities. The breakthrough therapy designation, which helps to expedite the development and review of the drug by the CDE, represent an encouraging signal to the promotion of MRG003 as well as the strategy of developing market-differentiating pipeline of the Company.
About Puyouheng (pucotenlimab injection) Puyouheng (pucotenlimab injection) is a humanized IgG4 monoclonal antibody against human PD-1 independently developed in China. It can bind to PD-1 with high affinity to restore the ability of immune cells to kill cancer cells by blocking the binding of PD-1 to its ligands PD-L1 and PD-L2. Puyouheng (pucotenlimab injection) adopts an innovative molecular design to prolong its half-life, showing strong clinical anti-tumor activity and good safety. The innovative use of antibody engineering technology to introduce triple mutations in the Fc region improves the binding affinity of FcRn, thereby prolonging the drug's half-life significantly, showing its promising clinical efficacy and drug compliance in patients. Compared with all rival anti-PD-1 antibodies that have been marketed or entered phase III clinical trials, the mean half-life of Puyouheng (pucotenlimab injection) is 21.8 days (single dosing) and 38.2 days (steady-state). In addition, the prolonged half-life does not cause additional adverse events, indicating the excellent clinical efficacy of the drug.
About MRG003 MRG003 is an ADC comprised of an EGFR-targeted monoclonal antibody ("mAb") conjugated with the potent microtublin inhibiting payload monomethyl auristatin E ("MMAE") via a valinecitrulline linker. It binds specifically with high affinity to EGFR on the surface of tumor cells, releases the potent payload upon internalization and lysosomal protease cleavage of the linker and results in tumor cell death. EGFR is highly expressed in colorectal cancer, lung cancer, head and neck cancer and other malignant solid tumors, and is expressed in 89% advanced NPC. Therefore, EGFR is an important target for cancer treatment. In China, the Company is conducting exploring research of MRG003 in several indications and amongst others, patient enrollment was completed in March 2022 for exploratory Phase II clinical study of MRG003 in advanced NPC. It has entered the follow-up period and clinical data is outstanding.
About LEPU BIOPHARMA LEPU BIOPHARMA is committed to innovation, focusing on the discovery, development and commercialization of first-in-class and best-in-class drug candidates in targeted anti-tumor therapy and immunotherapy drugs in China and the US. The company's mission is to develop the safest, most effective, and most accessible drugs for patients to improve their quality of life and fill the huge demand gap in the medical system. The company attaches great importance to the continuous construction of its commercialization capabilities, and strives to achieve a strong transformation from core technologies to finished drugs as well as the goal of industrialization. At present, the product pipeline of LEPU BIOPHARMA covers three major areas, namely immunotherapies, ADC targeted therapies and oncolytic virus drugs, including 1 commercially marketing drug and 7 drug candidates at the clinical stage (5 of which are ADC drugs) and the combination therapies of multiple major drug candidates at the clinical stage. The company houses the leading ADC drug candidate pipeline in China. https://en.lepubiopharma.com/
Source: Lepu Biopharma Co., Ltd. Sectors: BioTech, Healthcare & Pharm
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
 Executive Appointments in Connection with the Establishment of NESIC Holdings Jun 23, 2025 19:22 JST
|  Hua Medicine Announces at 2025 ADA Scientific Sessions that Dorzagliatin Combined with DPP-4 Inhibitor Shows Promise in Reducing Blood Lipids While Restoring Glucose Homeostasis Jun 23, 2025 13:05 JST
|  CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health Jun 20, 2025 19:06 JST
|  Sharp Launches A2 Size ePoster Color Electronic Paper Display Jun 19, 2025 12:08 JST
|  Fujitsu unveils AI-powered presentation technology, enabling automated multilingual and customizable presentations Jun 19, 2025 10:25 JST
|  ULVAC Continues Participation in "Lab-in-Fab" Project to Advance Piezoelectric MEMS Technology, Now Entering a New Phase Jun 19, 2025 09:30 JST
|  NEC and Chugai Pharmaceutical use AI to potentially enhance cancer treatment Jun 18, 2025 13:40 JST
|  Fujitsu awarded contract to design next-generation flagship supercomputer FugakuNEXT Jun 18, 2025 11:35 JST
|  Honda Celebrates 60th Anniversary of First F1 Victory with Special Events Program Jun 17, 2025 17:45 JST
|  MHI Receives Order to Supply 5 Models of Pumps, a Total of 34 Units, for Sizewell C Unit 1 and 2 in the UK from Trillium Flow Technologies Jun 17, 2025 17:10 JST
|  Honda Teams to Compete in 2025 FIM Endurance World Championship "Coca-Cola" Suzuka 8 Hours Endurance Road Race 46th Tournament Jun 16, 2025 16:37 JST
|  Fujitsu unveils Millimeter-Wave Monitoring System for enhanced safety and privacy in care facilities Jun 16, 2025 16:20 JST
|  Tat Hong Equipment Service Co., Ltd. Announces 2024/25 Annual Results Jun 13, 2025 22:49 JST
|  Yee Hop Holdings (1662.HK) Subsidiary APEL Launches Microfactory in Collaboration with HKPC Jun 13, 2025 21:38 JST
|  Jacobson Pharma Announces FY2025 Annual Results Jun 13, 2025 20:16 JST
|  TRENDE Announces Strategic Capital and Business Alliance with Tokyu Land Jun 13, 2025 13:00 JST
|  Supercomputer Fugaku retains first place worldwide in Graph500 rankings Jun 10, 2025 19:47 JST
|  International Consortium Rolls Out Major EV Battery Swapping Initiative in Tokyo Jun 06, 2025 16:42 JST
|  TANAKA PRECIOUS METAL TECHNOLOGIES Receives 2025 Technology Award from Catalyst Manufacturers Association, Japan, for Development and Practical Application of Electrode Catalysts for PEM Water Electrolysis Jun 06, 2025 11:00 JST
|  Fujitsu unveils Technology and Service Vision 2025: People-AI collaboration for a net positive future Jun 06, 2025 10:44 JST
|
More Latest Release >>
|